Guangzhou Lupeng Pharmaceutical Company Ltd.

This early-stage trial is testing an experimental drug called LP-168, taken as a pill, in adults with B-cell lymphoma that has come back or not responded to standard treatments. The study aims to find the safest dose and check for side effects in about 200 participants. It is too…

Researchers are testing an experimental drug called LP-108, a BCL-2 inhibitor, combined with azacitidine in adults with acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. The trial aims to find the highest dose people can tolerate and the best …

This early-stage trial tests a new drug called rocbrutinib combined with standard chemotherapy (R-GemOx) in 42 people with a type of lymphoma (DLBCL) that has returned or not responded to treatment. The main goals are to find a safe dose and see if the combination shrinks tumors.…

This trial is testing an experimental oral drug called rocbrutinib (LP-168) in people with relapsing-remitting multiple sclerosis (RRMS) who have a specific type of brain lesion called paramagnetic rim lesions. The study compares rocbrutinib to an existing treatment, dimethyl fum…

This study tests two experimental drugs (rocbrutinib and lacutoclax) taken together to treat several types of blood cancers, including lymphoma and leukemia. The goal is to see if the combination is safe and can shrink or control the cancer. About 92 adults who have already tried…

This phase 2 trial tests lacutoclax, a daily pill that blocks a protein helping cancer cells survive, in 75 adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants take the drug until their disease worsens or side effects become…

This Phase 3 trial tests a new drug called rocbrutinib against other targeted therapies for mantle cell lymphoma, a type of blood cancer. About 394 adults whose cancer has returned or not responded to previous treatment will be randomly assigned to receive rocbrutinib or another …

This study tests a new drug called rocbrutinib alone against standard treatments for a specific, aggressive type of lymphoma (non-GCB DLBCL) that has returned or not responded to prior therapy. About 150 adults will be randomly assigned to receive either rocbrutinib or a standard…

This early-stage study looks at how two common drugs—itraconazole (a fungus treatment) and rifampin (an antibiotic)—change the way the body processes rocbrutinib, an experimental medicine. About 28 healthy adults will take rocbrutinib alone and then with each other drug to measur…